Filing Analysis
Upstream Bio, Inc. filed an 8-K to furnish its quarterly financial results and business highlights for the period ended June 30, 2026.
📋 Key Facts
- Report date: August 11, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes a press release as Exhibit 99.1 containing financial results and business highlights.
- The company is an emerging growth company.
Upstream Bio, Inc. filed an 8-K to furnish its quarterly financial results and business highlights for the period ended September 30, 2025.
📋 Key Facts
- Report date: November 05, 2025
- Reporting Period: Quarter ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) containing financial results and business highlights.
- Company is an emerging growth company.
Upstream Bio, Inc. reported positive top-line results from its Phase 2 VIBRANT trial for verekitug in treating Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). The trial met both its primary and key secondary endpoints, demonstrating statistically significant clinical improvements.
📋 Key Facts
- Phase 2 VIBRANT trial evaluated verekitug (100 mg every 12 weeks) in 81 adults with CRSwNP over 24 weeks.
- Met primary endpoint: placebo-adjusted reduction in endoscopic nasal polyp score (NPS) of -1.8 (p<0.0001).
- Met key secondary endpoint: placebo-adjusted reduction in nasal congestion score (NCS) by -0.8 (p=0.0003).
- Observed significant reductions in the need for systemic corticosteroids or nasal polyp surgery.
- Safety profile was described as generally well tolerated with no serious adverse events observed.
Upstream Bio, Inc. filed an 8-K to furnish its quarterly financial results and business highlights for the period ending June 30, 2025.
📋 Key Facts
- Report date: August 6, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing includes results of operations and financial condition under Item 2.02
- Press release issued on August 6, 2025, is attached as Exhibit 99.1
Upstream Bio, Inc. held its 2025 Annual Meeting of Stockholders on June 10, 2025. The meeting resulted in the successful election of two Class I directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 10, 2025.
- Erez Chimovits was elected to serve as a Class I director until the 2028 annual meeting.
- Marcella Kuhlman Ruddy was elected to serve as a Class I director until the 2028 annual meeting.
- PricewaterhouseCoopers LLP (PwC) was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2025.
- As of April 14, 2025, there were 53,688,703 shares outstanding entitled to vote.
Upstream Bio, Inc. filed an 8-K to announce its financial results and business highlights for the fiscal quarter ended March 31, 2025.
📋 Key Facts
- Report date: May 6, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- The company is an emerging growth company
Upstream Bio, Inc. filed an 8-K to furnish its financial results and business highlights for the quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 12, 2025
- Reporting period: Quarter and Year ended December 31, 2024
- The filing includes a press release as Exhibit 99.1 containing financial results.
- Company is an emerging growth company.
Upstream Bio, Inc. filed an 8-K to furnish its quarterly financial results and business highlights for the period ending September 30, 2024.
📋 Key Facts
- Report date: November 7, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results and business highlights.
- The company is an emerging growth company.
Upstream Bio, Inc. filed an 8-K to amend its Certificate of Incorporation and Bylaws in connection with its initial public offering (IPO) effective October 10, 2024. The amendments primarily serve to restructure the company's capital structure and governance rules for its transition to a public entity.
🚩 Red Flags
- Elimination of stockholder rights to take action by written consent and call special meetings (standard for many IPOs but reduces shareholder control).
📋 Key Facts
- The Company filed its third amended and restated certificate of incorporation on October 15, 2024.
- Authorized common stock is set at 500,000,000 shares.
- The company eliminated all references to previously existing series of preferred stock.
- Authorized 10,000,000 shares of undesignated preferred stock for future issuance by the Board.
- Amended Bylaws eliminate the ability of stockholders to act by written consent or call special meetings.
- New advance notice procedures established for stockholder proposals and board nominations.